BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Amaral MD, Balch WE. Hallmarks of therapeutic management of the cystic fibrosis functional landscape. J Cyst Fibros 2015;14:687-99. [PMID: 26526359 DOI: 10.1016/j.jcf.2015.09.006] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Pierandrei S, Blaconà G, Fabrizzi B, Cimino G, Cirilli N, Caporelli N, Angeloni A, Cipolli M, Lucarelli M. Two novel and correlated CF-causing insertions in the (TG)mTn tract of the CFTR gene. PLoS One 2019;14:e0222838. [PMID: 31593572 DOI: 10.1371/journal.pone.0222838] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Borthwick LA, Kerbiriou M, Taylor CJ, Cozza G, Lascu I, Postel EH, Cassidy D, Trouvé P, Mehta A, Robson L, Muimo R. Role of Interaction and Nucleoside Diphosphate Kinase B in Regulation of the Cystic Fibrosis Transmembrane Conductance Regulator Function by cAMP-Dependent Protein Kinase A. PLoS One 2016;11:e0149097. [PMID: 26950439 DOI: 10.1371/journal.pone.0149097] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
3 Stanton BA, Hampton TH, Ashare A. SARS-CoV-2 (COVID-19) and cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2020;319:L408-15. [PMID: 32668165 DOI: 10.1152/ajplung.00225.2020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
4 Amaral MD. How to determine the mechanism of action of CFTR modulator compounds: A gateway to theranostics. Eur J Med Chem 2021;210:112989. [PMID: 33190956 DOI: 10.1016/j.ejmech.2020.112989] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
5 Beekman JM, Wang CM, Casati S, Tuggle KL, Gulmans VA, Amaral M, De Boeck K. Biobanking: towards increased access of biomaterials in cystic fibrosis. Report on the pre-conference meeting to the 13th ECFS Basic Science Conference, Pisa, 30 March-2 April, 2016. Journal of Cystic Fibrosis 2017;16:616-21. [DOI: 10.1016/j.jcf.2017.04.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
6 Amaral MD, de Boeck K; ECFS Strategic Planning Task Force on ‘Speeding up access to new drugs for CF’. Theranostics by testing CFTR modulators in patient-derived materials: The current status and a proposal for subjects with rare CFTR mutations. J Cyst Fibros 2019;18:685-92. [PMID: 31326274 DOI: 10.1016/j.jcf.2019.06.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
7 Vij N, Min T, Bodas M, Gorde A, Roy I. Neutrophil targeted nano-drug delivery system for chronic obstructive lung diseases. Nanomedicine 2016;12:2415-27. [PMID: 27381067 DOI: 10.1016/j.nano.2016.06.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 6.2] [Reference Citation Analysis]
8 Tosco A, Villella VR, Castaldo A, Kroemer G, Maiuri L, Raia V. Repurposing therapies for the personalised treatment of cystic fibrosis. Expert Opinion on Orphan Drugs 2018;6:361-73. [DOI: 10.1080/21678707.2018.1483231] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Hutt DM, Loguercio S, Campos AR, Balch WE. A Proteomic Variant Approach (ProVarA) for Personalized Medicine of Inherited and Somatic Disease. J Mol Biol 2018;430:2951-73. [PMID: 29924966 DOI: 10.1016/j.jmb.2018.06.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
10 Amaral MD, Hutt DM, Tomati V, Botelho HM, Pedemonte N. CFTR processing, trafficking and interactions. J Cyst Fibros 2020;19 Suppl 1:S33-6. [PMID: 31680043 DOI: 10.1016/j.jcf.2019.10.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
11 Roda J, Teixeira T, Ai Silva I, Silva TR, Ferreira R, Amaral MD, Oliveira G. Pediatric population with cystic fibrosis in the centre of Portugal: Candidates for new therapies. J Pediatr (Rio J) 2021:S0021-7557(21)00094-2. [PMID: 34252371 DOI: 10.1016/j.jped.2021.05.010] [Reference Citation Analysis]
12 Useckaite Z, Ward MP, Trappe A, Reilly R, Lennon J, Davage H, Matallanas D, Cassidy H, Dillon ET, Brennan K, Doyle SL, Carter S, Donnelly S, Linnane B, McKone EF, McNally P, Coppinger JA. Increased extracellular vesicles mediate inflammatory signalling in cystic fibrosis. Thorax 2020;75:449-58. [PMID: 32265339 DOI: 10.1136/thoraxjnl-2019-214027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 Colemeadow J, Joyce H, Turcanu V. Precise treatment of cystic fibrosis – current treatments and perspectives for using CRISPR. Expert Review of Precision Medicine and Drug Development 2016;1:169-80. [DOI: 10.1080/23808993.2016.1146077] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
14 Ferrari E, Monzani R, Villella VR, Esposito S, Saluzzo F, Rossin F, D'Eletto M, Tosco A, De Gregorio F, Izzo V, Maiuri MC, Kroemer G, Raia V, Maiuri L. Cysteamine re-establishes the clearance of Pseudomonas aeruginosa by macrophages bearing the cystic fibrosis-relevant F508del-CFTR mutation. Cell Death Dis 2017;8:e2544. [PMID: 28079883 DOI: 10.1038/cddis.2016.476] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 11.0] [Reference Citation Analysis]
15 Wang C, Balch WE. Bridging Genomics to Phenomics at Atomic Resolution through Variation Spatial Profiling. Cell Rep 2018;24:2013-2028.e6. [PMID: 30134164 DOI: 10.1016/j.celrep.2018.07.059] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 18.0] [Reference Citation Analysis]
16 Hutt DM, Mishra SK, Roth DM, Larsen MB, Angles F, Frizzell RA, Balch WE. Silencing of the Hsp70-specific nucleotide-exchange factor BAG3 corrects the F508del-CFTR variant by restoring autophagy. J Biol Chem 2018;293:13682-95. [PMID: 29986884 DOI: 10.1074/jbc.RA118.002607] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
17 Maiuri L, Raia V, Kroemer G. Strategies for the etiological therapy of cystic fibrosis. Cell Death Differ 2017;24:1825-44. [PMID: 28937684 DOI: 10.1038/cdd.2017.126] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
18 Pfaar O, Bonini S, Cardona V, Demoly P, Jakob T, Jutel M, Kleine-Tebbe J, Klimek L, Klysner S, Kopp MV, Kuna P, Larché M, Muraro A, Schmidt-Weber CB, Shamji MH, Simonsen K, Somoza C, Valovirta E, Zieglmayer P, Zuberbier T, Wahn U; FASIT group. Perspectives in allergen immunotherapy: 2017 and beyond. Allergy 2018;73 Suppl 104:5-23. [PMID: 29171712 DOI: 10.1111/all.13355] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 24.0] [Reference Citation Analysis]
19 Anglès F, Hutt DM, Balch WE. HDAC inhibitors rescue multiple disease-causing CFTR variants. Hum Mol Genet 2019;28:1982-2000. [PMID: 30753450 DOI: 10.1093/hmg/ddz026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
20 Villella VR, Tosco A, Esposito S, Ferrari E, Bona G, Kroemer G, Raia V, Maiuri L. Personalization of therapies in rare diseases: a translational approach for the treatment of cystic fibrosis. Minerva Pediatr 2019;71:362-70. [PMID: 30761822 DOI: 10.23736/S0026-4946.19.05511-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Wang C, Zhao P, Sun S, Teckman J, Balch WE. Leveraging Population Genomics for Individualized Correction of the Hallmarks of Alpha-1 Antitrypsin Deficiency. Chronic Obstr Pulm Dis 2020;7:224-46. [PMID: 32726074 DOI: 10.15326/jcopdf.7.3.2019.0167] [Reference Citation Analysis]
22 Shanthikumar S, Neeland MN, Saffery R, Ranganathan S. Gene modifiers of cystic fibrosis lung disease: A systematic review. Pediatr Pulmonol 2019;54:1356-66. [PMID: 31140758 DOI: 10.1002/ppul.24366] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
23 Hutt DM, Loguercio S, Roth DM, Su AI, Balch WE. Correcting the F508del-CFTR variant by modulating eukaryotic translation initiation factor 3-mediated translation initiation. J Biol Chem 2018;293:13477-95. [PMID: 30006345 DOI: 10.1074/jbc.RA118.003192] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
24 De Boeck K, Amaral MD. Progress in therapies for cystic fibrosis. The Lancet Respiratory Medicine 2016;4:662-74. [DOI: 10.1016/s2213-2600(16)00023-0] [Cited by in Crossref: 174] [Cited by in F6Publishing: 77] [Article Influence: 34.8] [Reference Citation Analysis]
25 Lim SH, Legere EA, Snider J, Stagljar I. Recent Progress in CFTR Interactome Mapping and Its Importance for Cystic Fibrosis. Front Pharmacol 2017;8:997. [PMID: 29403380 DOI: 10.3389/fphar.2017.00997] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
26 Esposito S, Tosco A, Villella VR, Raia V, Kroemer G, Maiuri L. Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis. Mol Cell Pediatr 2016;3:13. [PMID: 26976279 DOI: 10.1186/s40348-016-0040-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
27 Pollard BS, Pollard HB. Induced pluripotent stem cells for treating cystic fibrosis: State of the science. Pediatr Pulmonol 2018;53:S12-29. [PMID: 30062693 DOI: 10.1002/ppul.24118] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
28 Ricard-blum S, Miele AE. Omic approaches to decipher the molecular mechanisms of fibrosis, and design new anti-fibrotic strategies. Seminars in Cell & Developmental Biology 2020;101:161-9. [DOI: 10.1016/j.semcdb.2019.12.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
29 Reilly R, Mroz MS, Dempsey E, Wynne K, Keely SJ, McKone EF, Hiebel C, Behl C, Coppinger JA. Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis. Sci Rep 2017;7:7642. [PMID: 28794469 DOI: 10.1038/s41598-017-06588-z] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
30 Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, Burgel P, Tullis E, Castaños C, Castellani C, Byrnes CA, Cathcart F, Chotirmall SH, Cosgriff R, Eichler I, Fajac I, Goss CH, Drevinek P, Farrell PM, Gravelle AM, Havermans T, Mayer-hamblett N, Kashirskaya N, Kerem E, Mathew JL, Mckone EF, Naehrlich L, Nasr SZ, Oates GR, O'neill C, Pypops U, Raraigh KS, Rowe SM, Southern KW, Sivam S, Stephenson AL, Zampoli M, Ratjen F. The future of cystic fibrosis care: a global perspective. The Lancet Respiratory Medicine 2020;8:65-124. [DOI: 10.1016/s2213-2600(19)30337-6] [Cited by in Crossref: 183] [Cited by in F6Publishing: 82] [Article Influence: 183.0] [Reference Citation Analysis]